EDITOR: Haemorrhage associated with trauma and surgery remains a significant cause of death. The development of coagulopathic bleeding is often difficult to manage. Recombinant-activated factor VII (rFVIIa, NovoSeven®; Novo Nordisk, Bagsvaerd, Denmark), which is structurally similar to the naturally occurring activated coagulation factor VII, is licensed for use in patients with haemophilia A o...

Introduction We conducted a post-hoc analysis on the effect of recombinant factor VIIa (rFVIIa) on coagulopathic patients from two randomized, placebo-controlled, double-blind trials of rFVIIa as an adjunctive therapy for bleeding in patients with severe trauma. Methods Blunt and penetrating trauma patients were randomly assigned to rFVIIa (200 + 100 + 100 μg/kg) at 0, 1, and 3 hours after tran...

The recent commentary by Dr Torbey on “Intracerebral Hemorrhage: What’s Next?”1 has prompted us to share some data and thoughts on the use of activated factor VII (FVIIa, NovoSeven, Novo Nordisk A/S) in the management of intracerebral hemorrhage. FVIIa is approved to promote hemostasis in hemophiliacs with inhibitors. Studies have also suggested that it promotes hemostasis in nonhemophilic pati...

Thromb Haemost 2008; 100: 179–180 Protamine sulphate neutralizes the anticoagulant effect of unfractionated heparin (UFH), and this effect can easily be demonstrated by a variety of assay systems, including the traditional activated partial thromboplastin time (aPTT), as well as anti-factor Xa assays, or thrombin generation tests such as the Calibrated Automated Thrombogram (CAT) (1). Protamine...

contents   ◘ neoadjuvant chemotherapy in bladder cancer adib sereshki m.m. kashan university of medical sciences, iran 1 ◘ new advances of proteomics in early detection of pancreatic cancer adib sereshki m.m. kashan university of medical science, iran 1 ◘ peripheral blood changes in pulmonary tuberculosis before and after treatment eishi a., rahimi e. urmia university of medical sciences, iran ...